0.34
+0.0094(+2.81%)
Currency In USD
| Previous Close | 0.33 |
| Open | 0.34 |
| Day High | 0.36 |
| Day Low | 0.33 |
| 52-Week High | 1.3 |
| 52-Week Low | 0.22 |
| Volume | 604,146 |
| Average Volume | 2.21M |
| Market Cap | 7.51M |
| PE | -0.48 |
| EPS | -0.71 |
| Moving Average 50 Days | 0.4 |
| Moving Average 200 Days | 0.64 |
| Change | 0.01 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $3.4 as of September 29, 2025 at a share price of $0.344. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $4.54 as of September 29, 2025 at a share price of $0.344.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
GlobeNewswire Inc.
Sep 16, 2025 12:00 PM GMT
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use DisorderGLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDA
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
GlobeNewswire Inc.
Sep 03, 2025 12:30 PM GMT
GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
GlobeNewswire Inc.
Aug 20, 2025 12:30 PM GMT
U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory EnvironmentGLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“